<DOC>
	<DOC>NCT00666783</DOC>
	<brief_summary>This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tolerated in the Chinese cancer patients.</brief_summary>
	<brief_title>An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>Male or female, age ranging from 18 yrs to 70 yrs, with histologically or cytologically confirmed malignant disease naive to chemotherapy or nonnaive with an interval of at least 14 days to the last one Karnofsky index more than 70% and anticipated survival time more than 90 days Scheduled to receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the chemotherapy should be accomplished on study Day 1 No emetic episodes and antiemetic medication during the 24 hours preceding chemotherapy administration Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow function ) Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit Provision of written informed consent Inability to understand or cooperate with study procedures Receipt of investigational drugs 30 days before study entry Scheduled to receive any drug with antiemetic efficacy from 24 hrs before to 5 days after treatment Contraindications to 5HT3 receptor antagonists Woman Patient with Pregnancy or lactation Diagnosed with hypertension or severe infectious diseases Obstructive symptom of gastrointestinal tract Symptomatic brain metastasis or mental dysfunction Baseline QTc &gt; 500 ms</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>